Inactive Instrument

Governance Prana Biotechnology Limited Nasdaq

US7397271054

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jun. 03	Alterity Therapeutics Limited Announces Change of Registered Office Address	CI
May. 19	Alterity Therapeutics Announces Data Presentations Supporting Advancement Of ATH434 Into Phase 3 In Multiple System Atrophy	CI

Executive Committee: Prana Biotechnology Limited

Manager

Positions heldSince

David Stamler

65 year

Chief Executive Officer

2021-01-06

Margaret Bradbury

Chief Tech/Sci/R&D Officer

Abby Niven

Director of Finance/CFO	2024-09-29
Corporate Secretary	2024-11-17

Composition of the Board of Directors: Prana Biotechnology Limited

Director

CommitteesSince

Julian Barbaczy

Chairman

2025-11-20

Lawrence Gozlan

47 year

Audit Committee	2025-05-31
Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair

Peter Marks

70 year

Audit Committee	2013-09-24
Compensation Committee	2005-07-28
Audit Committee Chair	2019-04-22
Compensation Committee Chair	2019-04-22

Ann Cunningham

58 year

Governance Committee	2019-01-14
Nominating Committee	2019-01-14

David Stamler

65 year

Director/Board Member

2025-11-20

Former Officers and Directors: Prana Biotechnology Limited

Insider

Positions held

SinceUntil

Brian Meltzer

Director/Board Member	1999-12-08	2025-11-20
Independent Dir/Board Member	1999-12-08	2025-11-20

Geoffrey Kempler

Chief Executive Officer	2005-05-31	2021-01-06
Chairman	1997-11-10	2025-11-20
Founder	1997-11-10	2025-11-20
Investor Relations Contact	1997-11-10	-

Millie Macdonald

Investor Relations Contact

2025-08-31

Phillip Hains

Director of Finance/CFO	2024-01-30	2024-09-29
Corporate Secretary	2014-11-03	2024-11-17

Kathryn Andrews

Director of Finance/CFO

2014-11-03

2024-01-30

Tristan Edwards

Director/Board Member

2019-04-17

2022-01-03

David Sinclair

Director/Board Member

2019-04-07

2022-01-03

Ira Shoulson

Director/Board Member	2014-05-12	2019-04-07
Independent Dir/Board Member	2014-05-12	2019-04-07

George William Mihaly

Director/Board Member	1999-12-08	2019-04-07
Independent Dir/Board Member	1999-12-08	2019-04-07

Paul Marks

Director/Board Member

2011-01-03

Colin Louis Masters

Director/Board Member

2006-12-31

2007-07-01

Ross Murdoch

Chief Operating Officer	2002-09-19	2007-02-28
President	2002-09-19	2007-02-28

Jonas V. Alsenas

President

2005-06-15

Dianne Angus

Chief Operating Officer

2007-05-30

Richard Revelins

Director/Board Member	2010-12-21	2012-10-11
Director of Finance/CFO	2009-11-04	-
Corporate Secretary	2000-02-06	-

Nuket Desem

General Counsel

Matthew Corey

Director/Board Member

Hannah Howlett

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	5
Female	2

Of which Executive Committee

Male	2
Female	1

Of which Directors

Male	4
Female	1

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinsonâ€™s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Employees

Sector

More about the company